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Abstract
Backgrounds: Periprocedural myocardial injury (PMI) after elective percutaneous coronary intervention (PCI) significantly
influences the prognosis of coronary artery disease (CAD). However, it was unclear whether the occurrence of PMI was
associated with a series of controllable factors, such as PCI strategy or severity of CAD.
Methods: A total of 544 consecutive stable CAD patients underwent elective PCI were enrolled. The main outcome is
PMI, defined as troponin T after PCI was at least one value above the 99th percentile upper reference limit. Major adverse
cardiac events (MACE), including all-cause death, repeat myocardial infarction and target vessel revascularization were
record in the period of follow-up. Univariate and multivariate analysis was applied to assess predictors for the
occurrence of PMI.
Results: The incidence of PMI was 38.8% in the study. Compared with non-PMI patients (n = 333), PMI patients (n = 211)
had more diseased vessels, higher Gensini and Syntax score. Meanwhile, there were higher incidence of MACE in PMI
groups (9.5% vs. 3.2%, P < 0.01). We found that PMI patients underwent higher proportion of multi-vessel PCI
simultaneously (32.2% vs. 10.5%, P < 0.01) and had more stents implanted (1.8 ± 0.8 vs. 1.4 ± 0.6, P < 0.01). Importantly,
after simultaneously adjusted by other factors (such as age, diabetes, total cholesterol, number of diseased vessels,
Gensini score and stent length), the risk of PMI was still increased 84% by multi-vessel PCI independently (OR = 1.654,
95% CI = 1.004–2.720, P < 0.05).
Conclusions: The phenomenon of PMI occurred more commonly in stable CAD patients underwent multi-vessel PCI.
Multi-vessel international therapy could increase the risk of PMI in elective PCI.
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Background
Cardiac troponin T, which is highly sensitive and specific
biomarkers for myocardial injury [1], has been demon-
strated to be associated with the prognosis of coronary
artery disease (CAD). Increasing studies indicate that
troponin elevation after percutaneous coronary interven-
tion (PCI), which is relatively common after elective
coronary intervention [2–5], has been considered as one
of predictors for cardiac prognosis in CAD patients. It
has also been demonstrated that even minor elevation in
troponin T after elective PCI provides long-term prog-
nostic information regarding mortality and myocardial
infarction [5–8]. Therefore, it is critical for clinical prac-
titioners to assess or find out a series of controllable
factors or predictors for the occurrence of PMI, which
could be useful to reduce the risk of PMI. Tandjung K
found that number of implanted stents not stent type
was associated with the incidence of PMI [9]. Prasad also
confirmed that elevation of troponin T was not only
associated with angiographic characteristics, but also
provided long-term prognostic information [6]. How-
ever, there were few trials focused on multivariate
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analysis of the occurrence of PMI, and still fewer studies
reported on the eastern population with PMI, especially
in Chinese patients. Our previous study found that
periprocedural myocardial injury (PMI) was associated
with age, serum cholesterol and number of implanted
stents [10]. Number of implanted stents was mostly
determined by the severity of CAD during PCI proced-
ure; therefore, we speculated that PMI might be partly
impacted by severity of CAD or PCI strategy per se. In
order to clarify this hypothesis in Chinese patients, we
designed this study to demonstrate the clinical and PCI-
related risk factors of PMI, meanwhile, to clarify whether
the occurrence of PMI was associated PCI strategy (such
as stepwise PCI or multi-vessel PCI).
Methods
Study population
From October 2011 to June 2012, a total of 544 con-
secutive patients referred to our hospital with stable
angina pectoris for elective PCI were enrolled. The
inclusion criteria were: (1) patients with 18 to 85 years
of age; (2) providing a complete clinical history; (3)
underwent coronary stent implantation; (4) normal pre-
procedural troponin T (below the 99th percentile upper
reference limit (URL), <0.03 ng/ml [6]) and creatine
kinase (CK)-MB (<23U/L). The exclusion criteria were
as follows: (1) acute coronary syndrome; (2) elevated
cardiac troponin T (≥0.03 ng/ml) and CK-MB (≥23U/L)
before coronary intervention; (3) heart failure, cardiomy-
opathy, congenital heart diseases and heart valve diseases;
(4) treated coronary lesion was chronic total occlusion; (5)
recent surgery or trauma; (6) active chronic inflammation;
(7) dysfunction of hematological and immunological
system; (8) carcinoma or a condition treated with
immunosuppressive agents. We provided a written in-
formed consent form to participants in our study and
explained the entire study procedure to each patient.
This study and consent procedure were approved by
our local ethics committee (Ethics Committee of
Zhongshan Hospital affiliated to Fudan University),
and were carried out in accordance with the princi-
ples of the Declaration of Helsinki. Consent for publi-
cation of these data was obtained from each patient
when they were admitted in our hospital.
Clinical and laboratory measurements
The clinical characteristics of all patients including age,
gender, primary hypertension, diabetes, smoking history,
hyperlipidemia were recorded. Blood pressure and heart
rate admitted to hospital were also detected. Fasting
blood samples before PCI were drawn to detect
complete blood-cell counts and blood biochemistry.
High sensitive cardiac troponin T (hs-cTnT) was
measured before and within 24 h (from 10 to 20 h) after
PCI by immunoturbidimetry (Hitachi 7600-020 auto-
matic biochemistry analyzer). The 99th percentile upper
reference limit (URL) of hs-cTnT is 0.03 ng/ml (this
cut-point had been used in several previous studies, such
as Miller’s and Prasad’s studies [6, 11]). Patients with
post-procedural troponin T ≥ 0.03 ng/ml were defined as
PMI group (n = 211) and others were defined as non-
PMI group (n = 333).
Echocardiography
Echocardiography was performed in all patients using a
Philips IE33 instrument (Philips, Netherlands) with a
2–3.5 MHz transducer (X3-1), while left ventricular
ejection fraction (LVEF) were detected. Observers who
detected LVEF were blinded to the results of coronary
angiography and grouping.
Coronary angiography and intervention strategy
Elective coronary angiography was performed in all
patients after admission. A patient was considered to
have CAD when a stenosed lesion resulting in a 50%
or greater reduction in lumen diameter existed in at
least one of the coronary arteries. The severity of
CAD was evaluated by Gensini score and Syntax
score [12, 13]. Gensini score, Syntax score, number of
diseased vessels, diseased lesions, treated vessels and
implanted stents were recorded by observers who
were blinded to the results of laboratory testing and
study grouping. Patients with Gensini scores of 20 or
more were defined as having severe CAD, which was
approximately equal to one stenosed lesion of 70% or
more in the proximal left anterior descending artery.
The characteristics of lesions were also recorded and
classified according to ACC/AHA coronary lesion
classification [14].
Prior to PCI, all patients received adequate loading
doses of acetylsalicylic acid (300 mg) and clopidogrel
(30 mg). The PCI procedure was performed via the
femoral or radial access route. Interventional techniques
and further treatment during PCI were chosen at the
operators’ discretion and according to current standards.
Multi-vessel PCI was defined as more than one target
vessel PCI at this procedure.
Clinical outcomes
The primary outcomes evaluated for the present analysis
were major adverse cardiac events (MACE), which
including all-cause death, fatal or nonfatal myocardial
infarction (MI) and target vessel revascularization (TVR,
any clinically driven repeat PCI or bypass surgery of the
target vessel). The risk of target lesion revascularization
(TLR) was also analyzed.
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Statistical Analysis
All statistical analyses were performed with SPSS
software 19.0. Data were presented as the percentage or
mean ± standard deviation (SD). Chi-square analysis was
used to compare the frequency for categorical variables,
and Student’s t or correction t tests were used to
compare means for continuous variables. Correlation
analysis (Spearman test) was performed to evaluate the
correlations among serum level of post-procedural
troponin T, Gensini score and stent length. Multivariable
analysis (logistic) was performed to identify the inde-
pendent risk factors for PMI, to clarify whether the
Table 1 Comparison of clinical and laboratory characteristics







Male (%) 231 (69.4%) 147 (69.6%) 0.941
Age (year) 62.9 ± 9.1 66.4 ± 9.3 <0.01
Hypertension (%) 215 (64.6%) 151 (71.6%) 0.090
Hyperlipidemia (%) 102 (30.6%) 71 (33.6%) 0.674
Diabetes (%) 73 (22.0%) 64 (30.3%) 0.028
Smoking (%) 140 (41.4%) 73 (34.6%) 0.088
LVEF (%) 62.4 ± 6.7 60.3 ± 5.8 0.542
Systolic blood pressure
(mmHg)
127.8 ± 13.8 133.2 ± 15.9 0.105
Diastolic blood pressure
(mmHg)
76.3 ± 8.3 75.2 ± 8.1 0.544
Heart rate (beat per
minute)
69 ± 11 70 ± 8 0.802
Laboratory characteristics
eGFR (ml/min) 94.4 ± 20.4 92.6 ± 22.6 0.486
Total cholesterol
(mmol/L)
3.98 ± 1.02 4.26 ± 1.44 0.018
Triglyceride (mmol/L) 1.85 ± 0.96 2.04 ± 1.89 0.102
Pre-procedural CK-MB (U/L) 12.4 ± 5.8 13.9 ± 4.7 0.584
Post-procedural CK-MB (U/L) 18.5 ± 10.4 14.2 ± 5.6 0.054
Pre-procedure troponin
T (ng/ml)
0.014 ± 0.018 0.016 ± 0.017 0.872
Post-procedure troponin
T (ng/ml)
0.015 ± 0.021 0.156 ± 0.291 <0.01
Medication before angiography
Beta-blocker (%) 273 (82.0) 177 (83.9) 0.794
ACEI/ARB (%) 229 (68.8) 137 (64.9) 0.588
Aspirin (%) 301 (90.4) 184 (87.2) 0.536
Statin (%) 314 (94.3) 200 (94.8) 0.921
Abbreviations: ACEI/ARBs angiotensin-converting enzyme inhibitors/angiotensin
receptor blocker, CK creatine kinase, eGFR estimated glomerular filtration rate,
LVEF left ventricular ejection fraction, PMI Periprocedural myocardial injury
Table 2 Long-term Follow-up data of this study (median period:
18 months)
Non-PMI (n = 271) PMI (n = 170) P
MACE (%) 9 16 <0.01
TVR (%) 7 12 <0.01
Repeat MI (%) 2 3 0.386
All cause death (%) 0 1 0.616
TLR 5 9 <0.01
Abbreviations: MACE major adverse cardiac events, MI fatal or nonfatal
myocardial infarction, TLR target lesion revascularization, TVR target
vessel revascularization
Table 3 Comparison of Angiography and PCI characteristics









1.7 ± 0.8 2.2 ± 0.9 <0.01
Multi-vessel stenosis (%) 166 (49.8%) 157 (74.4%) <0.01
Number of diseased
lesions
2.5 ± 1.6 3.6 ± 2.0 <0.01
Average Gensini score 30.6 ± 20.0 43.3 ± 26.1 <0.01
Average Syntax score 12.7 ± 6.9 16.9 ± 9.0 <0.01
Severe CAD (%) 237 (71.2%) 194 (91.9%) <0.01
Target lesion characteristics –464 lesions –357 lesions
A (%) 86 (18.5%) 53 (14.8%) <0.01
B1 (%) 106 (22.8%) 64 (17.9%) <0.01
B2 (%) 110 (23.7%) 90 (25.2%) 0.048
C (%) 162 (34.9%) 150 (42.0%) <0.01
PCI characteristics
Number of target vessels 1.1 ± 0.4 1.3 ± 0.5 <0.01
Multi-vessel PCI (%) 35 (10.5%) 68 (32.2%) <0.01
Number of implanted
stents
1.4 ± 0.6 1.8 ± 0.8 <0.01
Total stent length (mm) 34.7 ± 17.8 49.4 ± 25.9 <0.01
Type of stents
–Sirolimus stent (%) 166 (49.8) 98 (46.4) 0.224
–Everolimus stent (%) 134 (40.2) 84 (40.0) 0.842
–Others (%) 33 (10.0) 29 (13.6) 0.218
Max inflation pressure
(atm)
13.3 ± 2.6 13.0 ± 1.7 0.762
Contrast volume (ml) 144.8 ± 47.3 172.3 ± 63.5 <0.01
Procedural complications
No reflow/slow reflow 4 (1.2%) 2 (1.0%) 0.682
Side-branch occlusion (%) 10 (3.0%) 12 (5.7%) 0.064
Distal thrombosis 1 (0.3%) 1 (0.5%) 0.342
Abbreviations: PCI Percutaneous coronary intervention, PMI Periprocedural
myocardial injury
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occurrence of PMI was associated PCI strategy (such as
stepwise PCI or multi-vessel PCI). All P-values were
two-sided, and P < 0.05 was considered to indicate statis-
tical significance.
Results
Population baseline characteristics and clinical outcomes
A total of 544 stable CAD patients underwent elective
PCI were enrolled in this study from October 2011 to
June 2012. There were 378 men (69.5%) and 166 women
(30.5%). The prevalence of hypertension, diabetes, and
hyperlipidemia were 67.2% (366 patients), 25.2% (137
patients) and 31.8% (173 patients), respectively. Eleva-
tion of post-procedural troponin T observed in 211
patients (38.8%) (Average troponin T level: 0.156 ±
0.291 ng/ml) were defined as PMI group. Patients with
normal post-procedural troponin T were defined as
non-PMI group (n = 333, average troponin T: 0.015 ±
0.021 ng/ml). Baseline clinical characteristics of these
patients were shown in Table 1.
The median period of follow-up in our study was
18.5 months. During the period of follow-up, 441 pa-
tients (81.0%) completed the clinical follow-up. The out-
come of MACE was significantly higher in PMI group
than that in non-PMI group (9.5% vs. 3.2%, P < 0.01).
We also found that the incidence of TLR was higher in
PMI groups (5.4% vs. 1.7%, P < 0.01) (Table 2).
Angiographic and procedural characteristics
There were 1032 diseased vessel in these 544 patients. A
total of 653 target vessels (1.2 target vessel per patient)
were implanted with drug-eluting stent (DES). Angio-
graphic characteristics were described in Table 3. Com-
pare with non-PMI patients, PMI patient suffered from
more severe CAD with higher Gensini score (43.3 ± 26.1
vs. 30.6 ± 20.0; P < 0.01), higher Syntax score (12.7 ± 6.9
vs. 16.9 ± 9.0, P < 0.01), more diseased vessels (2.2 ± 0.9
vs. 1.7 ± 0.8; P < 0.01) and more diseased lesions (3.6 ± 2.0
vs. 2.5 ± 1.6; P < 0.01). They also had more type C lesions
than those in non-PMI group (Table 3).
As concern to PCI characteristics (shown in Table 2),
we found that PMI patients had higher proportion of
multi-vessel PCI (32.2% vs. 10.5%, P < 0.01), more
implanted stents (1.8 ± 0.8 vs. 1.4 ± 0.6, P < 0.01) and
longer total length of implanted stents (49.4 ± 25.9 vs.
34.7 ± 17.8, P < 0.01).
PMI associated with severity of CAD
In order to clarify the association between occurrence of
PMI and the severity of CAD, subgroups analysis was
also performed in our study (Fig. 1). After stratified by
the number of diseased vessels, extent of Gensini score
and total length of implanted stents, we found that the
incidence of PMI was significantly increased in more
severe CAD patients.
Fig. 1 Incidence of PMI in patients stratified by severity of CAD
Fig. 2 Incidence of PMI in multi-vessel and single-vessel PCI patients stratified by age and diabetes
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Effect of Multi-vessel PCI on PMI
In this study, we found that patients with multi-vessel
PCI simultaneously underwent higher proportion of
PMI than those in single-vessel PCI group (66.0% vs.
32.8%, P < 0.01). In order to clarify the independent
effect of multi-vessel PCI on PMI, we re-analyzed the
effect of multi-vessel PCI after stratified patients by
other factors, such as age, diabetes, Gensini score, num-
ber of diseased vessel, number of stents and total stent
length. Multi-vessel PCI significantly increased the inci-
dence of PMI in each sub-group analysis (Figs. 2, 3 and
4). Stratified by number of diseased vessel, patients with
multi-vessel PCI had higher risk of PMI (2-vessel group:
57.8% vs. 37.7%; 3–4 vessel group: 72.4% vs. 45.2%, P <
0.01). While stratified by similar length of stents,
patients with multi-vessel PCI also had higher preva-
lence of PMI (<30 mm stent length: 57.1% vs. 24.9%;
30–50 mm stent length: 56.0% vs. 32.8%; >50 mm stent
length: 70.4% vs. 54.1%, P < 0.05).
Meanwhile, univariate analysis and multivariate logistic
analysis were used to evaluate independent effect of
multi-vessel PCI on the risk of PMI. In this analysis,
PMI was adjusted by age, diabetes, cholesterol, number
of diseased vessels, Gensini score, number of implanted
stents and stents length. No matter adjusted by single
factor or together, the risk of PMI was increased in-
dependently by multi-vessel PCI (OR = 1.654, 95%
CI = 1.004–2.720, P < 0.05) (Tables 4 and 5).
Discussion
As we know, PCI significantly improved the symptoms
and prognosis in CAD patients. However, PMI, which
occurred approximately 30% of patients after elective
PCI, has been one of critical problems [15, 16]. Several
previous studies documented that there was a significant
association between cardiac adverse prognosis and PMI
[6–8, 17, 18]. Therefore, another important thing is to
find out why and when PMI happens or what its risk
factors are.
Many prospective studies found that PMI patients
always combined with more severe coronary disease,
higher serum lipid level and more common clinical
complications [6, 10]. Prasad also reported that post-
procedural elevation of cardiac troponin was associated
with multi-vessel PCI. However, there was few multivari-
ate analysis applied between occurrence of PMI and its
risk factors. Multi-vessel disease must be associated with
severity of CAD, which could be demonstrated by sever-
ity score. Therefore, in order to eliminate the confound-
ing impact of disease severity and stent length (which
was related to PCI approach), multivariate logistic
analysis was applied. As we showed in Table 4, not only
patient-oriented factors, but also severity score, stents’
length and multi-vessel PCI approach were adjusted by
logistic analysis together. We found that even adjusted
by disease severity and stent length, multi-vessel PCI still
increase the risk of PMI independently. In previous
Fig. 3 Incidence of PMI in multi-vessel and single-vessel PCI patients stratified by severity of disease
Fig. 4 Incidence of PMI in multi-vessel and single-vessel PCI patients stratified by stent length and number
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studies [6], there was also significant difference of multi-
vessel PCI rate between PMI and non-PMI groups; how-
ever, it was only presented by univariate analysis. As we
know, multi-vessel PCI was not only determined by
multi-vessel disease and severe stenosis in each vessel,
but also presented as different numbers of stents and
different lengths of stents implantation. Therefore,
multivariate analysis was performed in our study, while
severity of CAD, numbers of stents and length of
implanted stents were controlled simultaneously.
In this study, Gensini score, Syntax score, number of
diseased vessel and number of implanted stents were
applied to evaluate the severity of CAD. We found that
occurrence of PMI was increased significantly in more
severe CAD patients (Fig. 1). It has been documented
that the most common mechanisms for PMI are distal
embolization or side branch occlusion [16, 19]. Vessel
lumen enlargement after stenting implantation probably
results in a combination of plaque compression, plaque
extrusion, plaque redistribution and micro-vessel
embolization [20]. Severe stenosed lesions, with large
lipid or necrotic core plaque, are at high risk of micro-
embolization during the procedure of lesion enlargement
and stents implantation [21]. Therefore, it is inevitable
for PCI to result in different extent of microemboliza-
tion. Post-procedural troponin T elevation may be a
marker for severe atherosclerosis, increased plaque
burden [22], presence of vulnerable plaques, endo-
thelial dysfunction, microvascular injury, and inflam-
mation [23].
Besides the severity of CAD, detailed PCI procedure
was also compared between PMI and non-PMI groups.
As we know, even among patients with the same
number of PCI vessels, they still presented as different
number and total length of implanted stents. Therefore,
the association between multi-vessel PCI and higher
prevalence of PMI might be confounded by number of
stents and length of stents. In order to clarify the inde-
pendent effect of multi-vessel PCI on PMI occurrence,
we re-evaluated the effect of multi-vessel PCI in
subgroup and multivariable analyses. When patients
were stratified by number of implanted stents and stents
length, incidence of PMI was increased significantly in
multi-vessel PCI group. Most importantly, after analyzed
by multivariate analysis, multi-vessel PCI was independ-
ently increased the risk of PMI.
We should note some of our study’s limitations.
First, the number of included patients was small size.
Second, it was a retrospective study, and its retro-
spective and non-randomized nature limited its
potency to clarify the association between PMI and
follow-up data. Third, present study did not include
routine intravascular ultrasound, which was quite
accuracy for lesion characteristic evaluation. These
limitations will be taken into account in our further
clinical researches and prospective studies.
Conclusions
The phenomenon of PMI occurred more commonly in
stable CAD patients underwent multi-vessel PCI. Multi-
vessel international therapy could increase the risk of
PMI in elective PCI.
Abbreviations
ACEI/ARBs: Angiotensin-converting enzyme inhibitors/angiotensin receptor
blocker; CAD: Coronary artery disease; CK: Creatine kinase; eGFR: Estimated
glomerular filtration rate; LVEF: Left ventricular ejection fraction; MACE: Major
adverse cardiac events; MI: Myocardial infarction; OR: Odds ratio; PCI: Percutaneous
coronary intervention; PMI: Periprocedural myocardial injury; TLR: Target lesion
revascularization; TVR: Target vessel revascularization
Table 4 Odds ratios of patient-oriented and PCI-oriented factors
for PMI (univariate analysis)




Age 1.043 1.023–1.063 <0.01
male 1.014 0.697–1.475 0.941
Diabetes 1.551 1.048–2.295 0.028
Hypertension 1.381 0.950–2.008 0.091
Total cholesterol 1.322 1.022–1.711 0.018
Triglyceride 1.150 0.940–1.408 0.102
PCI-oriented factors







Total stent length 1.032 1.023–1.041 <0.01
Multi-vessel PCI 4.092 2.588–6.469 <0.01
Abbreviations: PCI Percutaneous coronary intervention, PMI Periprocedural
myocardial injury
Table 5 Odds ratios of multivessel PCI for PMI adjusted by several
factors (multivariate logistic analysis)
Adjusted by OR 95% confidence
intervals
P
Multi-vessel PCI (not adjusted) 4.092 2.588–6.469 <0.01
Age 4.224 2.649–6.734 <0.01
Diabetes 3.965 2.503–6.282 <0.01
Total cholesterol 3.136 1.829–5.629 <0.01
Gensini score 2.809 1.717–4.595 <0.01
Number of diseased vessels 2.750 1.667–4.537 <0.01
Number of implanted stents 2.167 1.249–3.758 <0.01
Total stent length 2.323 1.330–3.745 <0.01
Adjusted by all these factors 1.654 1.004–2.720 0.045
Abbreviations: PCI Percutaneous coronary intervention, PMI Periprocedural
myocardial injury
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